Skip to main
INKT

MiNK Therapeutics (INKT) Stock Forecast & Price Target

MiNK Therapeutics (INKT) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiNK Therapeutics is a promising clinical-stage biopharmaceutical company with a focus on developing allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies for the treatment of cancer and other immune-mediated diseases. With a unique platform using iNKT cells and their therapeutic advantages, such as tissue homing and tumor clearance, MiNK Therapeutics has the potential for long-term success in the biopharmaceutical industry. While the company will likely need additional financing in the next two decades and faces delisting risk if share values drop, its focus on intellectual property protection adds another layer of stability and growth potential.

Bears say

MiNK Therapeutics is facing potential challenges in achieving its projected $35 price target as a result of factors such as safety concerns with clinical or preclinical programs, lower-than-expected efficacy, potential competition in the market, and regulatory obstacles. Our Buy rating and price target are contingent on the success of its single product candidate, agenT-797, for which we only assign value for two indications and have not factored in other pipeline assets in our valuation. (Words Count: 117)

MiNK Therapeutics (INKT) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiNK Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiNK Therapeutics (INKT) Forecast

Analysts have given MiNK Therapeutics (INKT) a Strong Buy based on their latest research and market trends.

According to 1 analysts, MiNK Therapeutics (INKT) has a Strong Buy consensus rating as of Jun 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $35, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $35, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiNK Therapeutics (INKT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.